Rationale and design of REGINA, a phase II trial of neoadjuvant regorafenib, nivolumab, and short-course radiotherapy in stage II and III rectal cancerGiacomo Bregni, Francesco Sclafani, Andrea Pretta et al.|Acta Oncologica|2021Cited by 11